1 / 26

23 rd November 2008

ranae
Download Presentation

23 rd November 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleasesElena E Perez, Jianbin Wang, Jeffrey C Miller, Yann Jouvenot, Kenneth A Kim, Olga Liu,Nathaniel Wang, Gary Lee, Victor V Bartsevich, Ya-Li Lee, Dmitry Y Guschin, Igor Rupniewski,Adam J Waite, Carmine Carpenito, Richard G Carroll, Jordan S Orange, Fyodor D Urnov,Edward J Rebar, Dale Ando, Philip D Gregory, James L Riley, Michael C Holmes & Carl H JuneNature Biotechnology, July 2008 Thalea Koithan 23rd November 2008

  2. HIV life cycle Universityof Washington (2004)

  3. CXCR4 and CCR5 coreceptors dual-tropic HIV strains

  4. CCR5 ∆32 deletion F. Arenzana-Seisdedos, M. Parmentier / Seminars in Immunology 18 (2006) 387–403

  5. ZFNs targeted against CCR5 • Zinc-finger nucleases (ZFNs) • Zinc-finger based DNA binding site • DNA cleavage domain • Introduce DSB

  6. ZFN-mediated disruption of CCR5 • FokI cleavage NHEJ Surveyor Assay • Denature and allow PCR products • to re-anneal to wildtype template. 2. Digest re-annealed products and analyze by PAGE.

  7. ZFN-mediated disruption of CCR5 • FokI cleavage NHEJ Surveyor Assay • GHOST-CCR5 cells • derived from human osteosarcoma cells • multiple CCR5 expression cassettes • Inducible GFP (under control of HIV-2 LTR) Cleaved products CCR5 ZFN-transduced high efficiency target gene mutations

  8. IL2Rγ ZFN CCR5 ZFN-224 IL2Rγ ZFN CCR5 ZFN-224 CCR5 ZFN-215 Nontransduced cells CCR5 ZFN-215 Unstained cells ZFN-mediated disruption of CCR5 • CCR5 ZFNs-transduced GHOST cells • After 1 week • Reduced CCR5 surface expression (>10-fold) • Decreased infection with CCR5-tropic HIV-1

  9. Resistance of CCR5 ZFN-treated GHOST-CCR5 cell clones to HIV infection • Isolation ofsinglecell-derivedclonesfrom ZFN-treated GHOST-CCR5 population • Completelyresistantto HIV-1 infection • infectionofcloneswithunmodified CCR5 genes Unstained cells CCR5 clone

  10. In vitro selection of CCR5-disrupted cells following HIV-1 challenge of the CD4+ T cell line PM1 • PM1 = CD4+ T cellline, similarlevelsof CCR5 expressiontoprimary CD4+ T cells

  11. In vitro selection of CCR5-disrupted cells following HIV-1 challenge of the CD4+ T cell line PM1 • CCR5 ZFN targetregionamplifiedby PCR (day 52 after HIV-1 infection) • Mutationsmappedtothecoreof ZFN recognitionsite • Permanent modificationof CCR5 by ZFN cleavageandrepair via NHEJ

  12. Enrichment of CCR5 ZFN-modified primary CD4+ T cells during in vitro HIV-1 challenge • Transductionof primary human CD4+ T cells

  13. Enrichment of CCR5 ZFN-modified primary CD4+ T cells during in vitro HIV-1 challenge Non-transduced HIV-1 infected ZFN-224 GFP-transduced mock infected • Indistinguishable population-doubling rate of modified • CD4+ T cells ZFN-224 transduced ( ) nontransduced cells ( ) • or control GFP transduced cells ( ) • Infectionwith CCR5-tropiv HIV-1 • 2x enrichmentofgene-editedcellswith ZFN-disrupted CCR5 alleles

  14. Enrichment of CCR5 ZFN-modified primary CD4+ T cells during in vitro HIV-1 challenge • Intranuclearstainingforgenome-wide DSB via immunodetectionof p53 bindingprotein 1 (53BP1) • recruitmentof 53BP1 tositesof DSBs early in repairresponse, requiredfor NHEJ • Quantificationof ZFN actionthroughoutthenucleus

  15. Enrichment of CCR5 ZFN-modified primary CD4+ T cells during in vitro HIV-1 challenge • Intranuclear 53BP1 foci transiently increased 1.4 – 1.6-fold • Etoposide-treated positive control cells had 4.2-fold increase in 53BP1 staining

  16. Determination of the consensus binding site for CCR5-ZFN • Production of randomized DNA oligonucleotides that specifically bind to the target ZFN • Sequence alignment for determination of consensus binding site sequence for zinc-finger DNA binding domain

  17. Determination of the consensus binding site for CCR5-ZFN • CCR2 is the only off-target with functions in CD4+ T cells • ZFN-224 has 10-fold lesser extend of activity at CCR2 (4.1%) than at CCR5 (35.6%)

  18. Reduction in viremia and selection for CCR5 ZFN-modified CD4+ T cells in the presence of HIV-1 challenge in vivo

  19. Reduction in viremia and selection for CCR5 ZFN-modified CD4+ T cells in the presence of HIV-1 challenge in vivo • Level of ZFN-disruptedCCR5 alleles in CD4+ T cellsisolated on day 40 fromspleens • 3-fold enrichmentfor ZFN-disruptedCCR5 alleles in HIV-infectedgroup

  20. Reduction in viremiaandselectionfor CCR5 ZFN-modified CD4+ T cells in thepresenceof HIV-1 challengein vivo • 50 days after infection 8 of 10 HIV-infected mice >50% CCR5-disrupted CD4+ T cells in peripheral blood

  21. Reduction in viremia and selection for CCR5 ZFN-modified CD4+ T cells in the presence of HIV-1 challenge in vivo • 10 days post infection • less HIV-1 viral RNA in CCR5 ZFN-treatedmice • Engraftmentof CD4+ T cells in peripheralblood • CCR5 ZFN-treatedmicehadhigher CD4+ T cellcounts on day 30-50 p.i. CCR5 ZFN GFP

  22. Summary I • CCR5 ZFNs efficiently cleave their target site in CCR5 • HIV-1 infection provides a potent selective advantage for CCR5 ZFN-modified cells • Modified CD4+ T cells confer resistance to HIV infection in vivo by • >50% CCR5-disrupted CD4+ T cells in peripheral blood • Increased numbers of CD4+ T cells • Lower plasma viremia • Transient delivery of engineered ZFNs could mimic the selective advantage of naturally occurring CCR5∆32 null mutation in humans for resistance to CCR5-tropic HIV-1 • Potential to reconstitute immune function by maintainance of an HIV-resistant CD4+ T cell population for clinical trials

  23. CCR5 versus CXCR4

  24. ZFN

More Related